Member Info for HallsWorthy

I do wonder what more a company and leader has to do for people to realise it's a lifestyle company, paid for by you

They're already generating a return

I don't know at what point you think it's acceptable to be unhappy? Are you ok with the progress here? They've done absolutely nothing they said they would. I'm amazed any holder can sit here and defend poolbegs as it stands

Some cash? A bit of AI? A big expensive management team that achieve nothing?

It does feel like Cathal saw the dollar signs when he got that initial fundraise and got all his mates along for a few years long booze up til the pot runs dry.

I think we're at the point we can consider this worthless now. If it was remotely exiting to a large pharmaceutical it would be long, long gone.

Best to focus on other avenues

By all measures it's a reputable, decent company

The transaction values the shell at £2.5m prior to any placing

He's just clutching at straws as always, think most people can tell a response isn't fabricated and it's easy to disprove - email investor relations and you'll probably get a copy and paste of the same message yourself

Nice reply carrot but just not worth conversing with the chump. I tried and he won't ever engage in any meaningful debate. He doesn't fundamentally understand the stock market nor relatively obvious aspects of pharma or CROs; best to ignore

Hopefully a climb back to 30 and a load of comments about what was all the fuss about. Certainly HVOs investor relations response suggest it was nothing more than private investors panic and snowball but it would be nice to see a new Tr1 increase from octopus all the same

£62m revenue, circa £40m cash, Mcap of £149m and the share price finally showing strength - what's not to love?

Thanks for your email. The company is of course aware of the recent share price weakness but is concentrated on factors within its control. hVIVO reiterated its guidance in September for £62 million in revenue with full year EBITDA margins anticipated to be at the upper end of market expectations for 2024, and there has been no change to this.

If there are any material changes to expectations, the company would be required to issue an RNS to update the market. It is not in the company’s interest to make a habit of commenting on movements in share price or the decision-making of individual investors, for which there is a large number of contributing influences.

It is in the nature of hVIVO’s business model for there to be gaps between contract announcements. Decisions on whether clients proceed with a challenge trial are complex and affected by a number of different factors outside of hVIVO’s control. The Company did announce in its interim results that it had a pipeline of live short to medium term opportunities of c. £40million. The company remains confident in the long-term growth of the business and human challenge trial market, and its medium term growth target of growing Group revenue to £100 million by 2028.

I hope this helps.

Kind regards,

Louis

Someone rather helpfully uploaded it to YouTube but I think it's been pulled now

All the company needs to say is the usual "no known reason for this fall" and confirmation nothing has changed. Guidance for 2025 revenue wouldn't go amiss though. I'm very disappointed they havent already done so as the more proper companies do this routinely.

Sub 20 should be a flood of buys not sells

I just picked up 15k+ plus at 21.77 as it just seems like a stupid price for a share with approx 40m in the bank and significant pipeline and revenue. I don't believe octopus will leave their foot off the accelerator for much longer and could realistically push the price back up to nudge 30 given their previous buying levels

It's a real shame they don't seem to do with reverse speeding tickets in HVO, it's such a simple way to stem the flow

Thanks for your email.

 

It is difficult to discern exactly what the cause of the share price fall is – any material news about the Company’s financial expectations would need to be disclosed to the market, so you can safely assume there have been no changes on that front. In terms of institutional investors, Octopus has continued to buy into hVIVO (they reached a holding of 13.32% this week).

 

We have received some inbounds from retail investors who have expressed concern about lack of contract newsflow, as well as regarding upcoming political changes in the US.

 

The Company is confident that the continued development of new vaccines and antivirals is imperative to improving global health, and that this view is reflected by global biopharma. hVIVO works with four of the top 10 global biopharma companies and a number of repeat biotech clients year-on-year, which demonstrates the strong support for the use of human challenge trials in speeding up clinical development.

 

Regarding contract announcement timings, it is in the nature of hVIVO’s business model for there to be gaps between contract announcements. Decisions on whether clients proceed with a challenge trial are complex and affected by a number of different factors outside of hVIVO’s control, and the Company the charges an upfront non refundable deposit on booking which ensures that clients are fully committed to proceeding with a study at signature and that its orderbook has a high conversion rate into revenue. hVIVO does not announce low value contracts and will continue to announce significant value or strategically important contracts, though the Company did announce in its interim results that it had a pipeline of live short to medium term opportunities of c. £40m.

 

Kind regards,

I have had a response from investor relations confirming they are on track, so you'll have to find a new angle

You saying 2025 revenues are in jeopardy doesn't mean they are. I have ha